74 related articles for article (PubMed ID: 8742624)
1. [The ipriflavone story].
György L; Mihály N; Marian EP; István H
Acta Pharm Hung; 1995 Nov; 65(6):191-4. PubMed ID: 8742624
[TBL] [Abstract][Full Text] [Related]
2. [Place of ipriflavone in the therapy of osteoporosis].
Zsuzsanna B
Acta Pharm Hung; 1995 Nov; 65(6):229-32. PubMed ID: 8742631
[TBL] [Abstract][Full Text] [Related]
3. [Overview of clinical studies with ipriflavone].
Attila BK
Acta Pharm Hung; 1995 Nov; 65(6):223-8. PubMed ID: 8742630
[TBL] [Abstract][Full Text] [Related]
4. [Effects of ipriflavone on bone loss induced by GnRH analog].
Pellicano M; Morgera R; Affinito P; Di Carlo C; Napolitano V; Merlino P; Tremolaterra F; Palomba S; Nappi C
Minerva Ginecol; 1996 Oct; 48(10):435-9. PubMed ID: 9005368
[TBL] [Abstract][Full Text] [Related]
5. Effect of ipriflavone--a synthetic derivative of natural isoflavones--on bone mass loss in the early years after menopause.
Gennari C; Agnusdei D; Crepaldi G; Isaia G; Mazzuoli G; Ortolani S; Bufalino L; Passeri M
Menopause; 1998; 5(1):9-15. PubMed ID: 9689189
[TBL] [Abstract][Full Text] [Related]
6. Ipriflavone: an important bone-building isoflavone.
Head KA
Altern Med Rev; 1999 Feb; 4(1):10-22. PubMed ID: 9988779
[TBL] [Abstract][Full Text] [Related]
7. [Experience with ipriflavone therapy in postmenopausal osteoporosis].
Szántó F
Orv Hetil; 1997 Nov; 138(44):2801-3. PubMed ID: 9411349
[TBL] [Abstract][Full Text] [Related]
8. Ipriflavone modulates IGF-I but is unable to restore bone in rats.
Deyhim F; Smith BJ; Soung DY; Juma S; Devareddy L; Arjmandi BH
Phytother Res; 2005 Feb; 19(2):116-20. PubMed ID: 15852487
[TBL] [Abstract][Full Text] [Related]
9. Ipriflavone, an antiostheophorotic agent.
Böcskei Z; Simon K; Varga M; Hermecz I
Acta Crystallogr C; 1996 Apr; 52 ( Pt 4)():1022-4. PubMed ID: 8624237
[TBL] [Abstract][Full Text] [Related]
10. Ipriflavone not effective for osteoporosis.
Harv Womens Health Watch; 2001 Jun; 8(10):5. PubMed ID: 11439282
[No Abstract] [Full Text] [Related]
11. Ipriflavone.
Altern Med Rev; 2000 Jun; 5(3):260-3. PubMed ID: 10869105
[No Abstract] [Full Text] [Related]
12. Ipriflavone: A New Non-Hormonal Therapeutic Agent in Osteoporosis. Satellite symposium proceedings. Florence, Italy, April 24, 1992.
Bone Miner; 1992 Oct; 19 Suppl 1():S1-64. PubMed ID: 1358372
[No Abstract] [Full Text] [Related]
13. [Dietary phytoestrogen and its potential benefits in adult human health].
Garrido A; de la Maza MP; Valladares L
Rev Med Chil; 2003 Nov; 131(11):1321-8. PubMed ID: 14743696
[TBL] [Abstract][Full Text] [Related]
14. Proceedings from a symposium of basic research on ipriflavone (Osten). Yokohama, Japan. January 18, 1992.
Calcif Tissue Int; 1992; 51 Suppl 1():S1-34. PubMed ID: 1358419
[No Abstract] [Full Text] [Related]
15. Ipriflavone metabolite-III inhibits LPS-induced nitric oxide release from RAW-264.7 cells.
Koncz S; Horváth EJ
Acta Physiol Hung; 1996; 84(3):223-8. PubMed ID: 9219593
[TBL] [Abstract][Full Text] [Related]
16. Ipriflavone: background.
Gennari C
Calcif Tissue Int; 1997; 61 Suppl 1():S3-4. PubMed ID: 9263607
[No Abstract] [Full Text] [Related]
17. [Pharmacokinetics of ipriflavone].
Ferenc L; István S
Acta Pharm Hung; 1995 Nov; 65(6):219-22. PubMed ID: 8742629
[TBL] [Abstract][Full Text] [Related]
18. Soy and its isoflavones: a review of their effects on bone density.
Brynin R
Altern Med Rev; 2002 Aug; 7(4):317-27. PubMed ID: 12197783
[TBL] [Abstract][Full Text] [Related]
19. [Metabolism of ipriflavone].
Ferenc L; István S
Acta Pharm Hung; 1995 Nov; 65(6):215-8. PubMed ID: 8742628
[TBL] [Abstract][Full Text] [Related]
20. [Forced stability study of ipriflavone].
Magdolna VM; Kálmán S; Imola R; Tünde ET; István H
Acta Pharm Hung; 1995 Nov; 65(6):203-7. PubMed ID: 8742626
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
